R
Ultragenyx Pharmaceutical D
D
RARE
40.000
USD
0.48
(1.21%)
مغلق
حجم التداول
20,218
الربح لكل سهم
-5
العائد الربحي
-
P/E
-7
حجم السوق
3,781,681,400
الأخبار المقالات
العنوان: Ultragenyx Pharmaceutical
القطاع: Healthcare
الصناعة: Biotechnology
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.